Wegovy 1 mg/0.5 ml: the third step on the titration schedule

What the licensed titration schedule tells us about 1 mg

Wegovy's titration pathway (published in the Summary of Product Characteristics and summarised on the NHS semaglutide medicines page) moves through five strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, each held for approximately four weeks before the next increase. The 1 mg step is therefore the midpoint of that climb. It exists for a practical reason: semaglutide slows gastric emptying and reduces appetite through the GLP-1 receptor, and stepping the dose upward gives the body time to adapt before the next increase rather than jumping straight to a higher concentration.

The STEP 1 trial, published in the New England Journal of Medicine, studied semaglutide 2.4 mg against placebo over 68 weeks and reported an average body-weight reduction of around 15% at the full maintenance dose. The 1 mg step does not produce that outcome on its own (the trial was designed around reaching and staying at 2.4 mg) but without moving through the intermediate doses, most people would not tolerate the maintenance dose at all. Think of 1 mg as the schedule doing its job, not falling short of it.

One thing worth saying plainly: if you are reading this page mid-treatment and feeling uncertain about your progress here, that is genuinely understandable. Weight loss at intermediate doses is rarely linear, and the weeks between 0.5 mg and your eventual maintenance dose can feel slow. That is normal, and it is not a sign the medicine is not working for you.

Side effects at the 1 mg dose and what the evidence says

Gastrointestinal effects (nausea, loose stools, constipation, indigestion, reflux) are the most commonly reported across all semaglutide doses. They tend to be most noticeable in the first few days after a dose increase, then settle for most people within a week or two. Moving from the 0.5 mg/0.5 ml pen to 1 mg follows that same pattern. For practical detail on what to expect and how to manage it, the Wegovy overview page covers the side-effect profile in full.

There is one urgent signal worth knowing. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines highlighting that acute pancreatitis, while infrequent, can be serious: severe stomach pain that does not pass and may radiate toward the back, with or without vomiting, warrants prompt medical attention. This applies across all doses, not just higher ones. If you experience that symptom pattern, stop the injection and seek help rather than waiting for your next scheduled review. Other signs to act on quickly include symptoms of a severe allergic reaction or significant dehydration from persistent vomiting or diarrhoea.

Injection-site reactions (mild redness or tenderness) are also possible. Rotating between the abdomen, thigh and upper arm from week to week reduces that risk. Your Patient Information Leaflet gives precise guidance on technique and storage; the electronic Medicines Compendium holds the full Wegovy SmPC if you want the prescribing-level detail.

Who reaches the 1 mg step and when to move beyond it

In straightforward terms: anyone starting Wegovy on the standard schedule will pass through 1 mg after approximately eight weeks on treatment, assuming the earlier doses were tolerated. The journey there begins with the 0.25 mg/0.5 ml starting dose, which is where the body first encounters semaglutide and the lowest-intensity adaptation begins. Others progress on schedule. Neither path is wrong; the schedule is a guide, not a countdown.

The decision to advance from 1 mg to 1.7 mg belongs entirely to your prescriber. At a service like nume, that means a real clinician reviews your situation before any repeat or dose change, not an automated system. If you want to understand what that review covers and how it works, the about us page describes our clinical process in detail, and our clinical team profile introduces the prescribers who carry out that work.

It is also worth noting that Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition. Lower thresholds may apply for certain ethnic backgrounds under UK guidance. BMI alone does not determine suitability, the prescriber weighs up the whole picture. If you are thinking about starting treatment rather than progressing through it, the consultation hub is the right place to begin, and you can also find specific information about the 0.5 ml Wegovy format alongside Wegovy pricing in the UK to help set realistic expectations before you do.